Catalyst Pathways^®: Your Path to a Better Tomorrow

Duchenne muscular dystrophy (DMD) is a rare genetic disorder that causes progressive muscle weakness. People living with DMD and their families face a variety of challenges every day. A path to prompt, affordable treatment should not be one of them. That is why Catalyst Pharmaceuticals created Catalyst Pathways^®, a free program that offers personalized support and assistance to people taking AGAMREE^® (vamorolone). AGAMREE is approved to treat DMD in patients as young as 2 years old. To learn more, visit AGAMREE.com.

Catalyst Pathways provides patients and their families with helpful and easy to understand information about DMD and AGAMREE, as well as services designed to ease their treatment experience.

Once a patient starts taking AGAMREE, Catalyst Pathways provides intuitive, comprehensive one-on-one support. When prescribed AGAMREE, a patient or caregiver can complete the Catalyst Pathways Enrollment Form with their healthcare provider or call 1-833-4-CATALYST. After enrollment, a Care Coordinator is assigned who passes along important information. The patient or caregiver will then connect with the rest of their dedicated team, including:

• Insurance Navigator: Handles complicated coverage and reimbursement issues and works to resolve them
• Patient Access Liaison (PAL): Patient’s go-to local resource for education and treatment support when and where it is needed most

“It may feel like you have no one to talk with about what you’re experiencing, and like you don’t know where to turn for information. Remember that Catalyst Pathways and your Patient Access Liaison are here to help.”

– Martha, Catalyst Pathways Patient Access Liaison

A PAL is the bridge to interactive support programs offered by Catalyst Pathways. The patient and their family will be invited to Coffee Breaks, a virtual or in-person discussion with patients and families living with DMD and taking AGAMREE. Each Coffee Break covers an important topic and helps to build a strong local community. Catalyst Pathways also offers the AGAMREE Connect, Educate, and Support (ACES) Learning Series program, which encompasses the AGAMREE caregiver ambassador and mentor program. Through the ACES program, caregivers for a patient living with DMD will be introduced to other experienced caregivers. Together, they can discuss their treatment journeys and share useful tips and information about the challenges faced by patients and families living with DMD. The Ambassador Program is a virtual and in-person outreach program where a caregiver shares their story with patients, providing them with an opportunity to learn more about Agamree.

“You can meet with your PAL in person or over the phone. That sort of personalized care is what really makes this program so special.”  

– Andrea, Catalyst Pathways Patient Access Liaison

In addition to support and community building opportunities, Catalyst Pathways offers financial assistance through a variety of programs:

• Catalyst Bridge Program: While patient insurance coverage is being reviewed, Catalyst Pathways will provide qualifying patients enrolled in the program with a “Bridge” medicine (free medicine to carry eligible patients over the gap between insurance investigation and confirmation of coverage, some restrictions may apply)
• Copay Assistance: For patients with commercial insurance, Catalyst Pathways lowers out-of-pocket costs to $0/month
• Patient Assistance Program: If a patient’s insurance coverage is denied, Catalyst Pathways provides free medicine to qualifying patients for as long as it’s needed

If you or a member of your family is living with DMD, consider talking to your healthcare provider about AGAMREE. To discover ways Catalyst Pathways can support you or a member of your family, visit AGAMREE.com/patient-support.

To learn more about how Catalyst Pathways can provide a clear path to prompt, affordable treatment, visit YourCatalystPathways.com or call 1-833-4-CATALYST and experience our personalized support and assistance.

“Catalyst Pathways is there to support you each step of the way.”

– Martha, Catalyst Pathways Patient Access Liaison

What is AGAMREE?

AGAMREE is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

Patients should not take AGAMREE if they are allergic to vamorolone or any of the inactive ingredients in AGAMREE.

What is the most important information I should know about AGAMREE?

• Do not stop AGAMREE, or change the amount taken, without first checking with your healthcare provider. There may be a need for gradual dose reductions to decrease the risk of adrenal insufficiency crisis, which can be fatal.
• There is an increased risk of infection when taking corticosteroids like AGAMREE. Tell your healthcare provider if the patient has had recent or ongoing infections or has recently received a vaccine. Seek immediate medical advice in the case of fever or other signs of infection. Some infections can be severe, and sometimes fatal. Patients should avoid exposure to chickenpox or measles; alert your healthcare provider immediately if exposure occurs.
• Corticosteroids, including AGAMREE, can cause an increase in blood pressure and water retention. Your healthcare provider may monitor for these increases during treatment.
• There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like AGAMREE.
• Corticosteroids, including AGAMREE, can cause severe behavioral and mood changes. Seek medical attention if behavioral or mood changes develop.
• There is a risk of osteoporosis with prolonged use of corticosteroids like AGAMREE, which can lead to vertebral and long bone fractures.
• Corticosteroids like AGAMREE may cause cataracts or glaucoma. Your healthcare provider should monitor for these conditions if AGAMREE treatment continues for more than 6 weeks.
• Immunizations should be up to date according to immunization guidelines prior to starting therapy with AGAMREE. Live‑attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting AGAMREE. Live‑attenuated or live vaccines should not be administered in patients taking AGAMREE.
• Rare instances of severe allergic reaction have occurred in patients receiving corticosteroid therapy.

Before taking AGAMREE, tell your healthcare provider about all medical conditions, including if the patient:

• has decreased liver function.
• is pregnant or planning to become pregnant. AGAMREE can harm an unborn baby.
• is breastfeeding or planning to breastfeed. AGAMREE may appear in breastmilk and could affect a nursing child.

Certain medications can cause an interaction with AGAMREE. Tell your healthcare provider about all the medicines the patient takes, including prescription and over-the-counter medicines, dietary supplements, and herbal products.

What are the possible side effects of AGAMREE?

The most common side effects with AGAMREE include facial puffiness (cushingoid features), psychiatric disorders, vomiting, weight gain, and vitamin D deficiency. These are not all the possible side effects of AGAMREE.

Call your doctor for medical advice about side effects.

Please see full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals, Inc. at 1-844-347-3277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

AGAMREE is a registered trademark of Santhera Pharmaceuticals (Schweiz) AG.
Catalyst Pathways is a registered trademark of Catalyst Pharmaceuticals, Inc.
© 2025 Catalyst Pharmaceuticals, Inc. All Rights Reserved. AGA-0471-1 June 2025